Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?
1990; Wiley; Volume: 30; Issue: 4 Linguagem: Inglês
10.1111/j.1365-2125.1990.tb03807.x
ISSN1365-2125
Autores Tópico(s)Drug-Induced Adverse Reactions
ResumoBritish Journal of Clinical PharmacologyVolume 30, Issue 4 p. 501-510 Free Access Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow? T Pullar, T Pullar Department of Medicine, University of Leeds.Search for more papers by this author T Pullar, T Pullar Department of Medicine, University of Leeds.Search for more papers by this author First published: October 1990 https://doi.org/10.1111/j.1365-2125.1990.tb03807.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References Anon (1982). Benoxaprofen. Br. med. J., 285, 459– 460. Ash, G., Baker, R., Rajapakse, C. & Swinson, D. R. (1986). Study of sulphamethoxazole in rheumatoid arthritis. Br. J. Rheumatol., 25, 285– 287. Astbury, C., Hill, J. & Bird, H. A. (1986). Cotrimoxazole in rheumatoid arthritis. Br. J. Rheumatol., 26, (Abstract Suppl. 1), 9. Belch, J. J. F., Madhok, R., McArdle, B., McLaughlin, K., Kluft, C., Forbes, C. D. & Sturrock, R. D. (1986). The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol. Quart. J. Med., 58, 19– 27. Bird, H. A., Burkinshaw, L., Pearson, D., Atkinson, P. J., Leatham, P. A., Hill, J., Raven, A. & Wright, V. (1987). A controlled trial of nandrolone decanoate in the treatment of rheumatoid arthritis in postmenopausal women. Ann. Rheum. Dis., 46, 237– 243. Bird, H. A., Hill, J., Sitton, N. G., Dixon, J. S. & Wright, V. (1988a). A clinical and biochemical assessment of etidronate sodium in patients with active rheumatoid arthritis. Clin. Rheumatol., 7, 91– 94. Bird, H. A., Hill, J. S., Sitton, N. G., Dixon, J. S. & Wright, V. (1988b). A clinical and biochemical evaluation of etretinate in rheumatoid arthritis. Rheumatol. Int., 8, 55– 59. Bird, H. A., Le Gallez, P., Dixon, J. S., Catalano, M. A., Traficante, A., Lianw, L., Sussman, H., Rotman, H. & Wright, V. (1990). A clinical and biochemical assessment of a non-thiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis. J. Rheumatol., 17, 603– 608. Borg, G., Allander, E., Lund, B., Berg, E. & Brodin, U. (1988). Auranofin improves outcome in early rheumatoid arthritis: results from a 2-year, double-blind, placebo controlled study. J. Rheumatol., 15, 1747– 1754. Bunch, T. W., O'Duff, J. D., Tomkins, R. B. & O'Fallon, W. M. (1984). Arthritis & Rheumatism, 27, 267– 276. Cannon, G. W., Pincus, S. H., Emkey, R. D., Denes, A., Cohen, S. A., Wolfe, F., Saway, P. A., Jaffer, A. M., Weaver, A. L., Cogen, L. & Schindler, J. D. (1989). Double-blind trial of recombinant γ-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis & Rheumatism, 32, 964– 973. Cox, N. L., Maddison, M. C. & Maddison, P. J. (1989). Rifampicin and isoniazid do not work in early RA. Br. J. Rheumatol., 28 (Abstract Suppl. 1), 23– 24. Dixon, J. S., Bird, H. A., Pickup, M. E. & Wright, V. (1982). A human model screening system for the detection of specific anti-rheumatic activity. Sem. Arthritis Rheum., 12, 185– 190. Dixon, J. S., Bird, H. A., Surrall, K. E., Sitton, N. G. & Wright, V. (1984). A comparison of therapies which may influence trace metals in rheumatoid arthritis. Clin. Rheumatol., 3, 451– 458. Dougados, M., Awada, H. & Amor, B. (1988). Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann. Rheum. Dis., 47, 127– 133. Egsmose, C., Lund, B. & Andersen, R. B. (1988). Timegadine: more than a non-steroidal for the treatment of rheumatoid arthritis. A controlled, double-blind study. Scand. J. Rheumatol., 17, 103– 111. Empire Rheumatism Council (1960). Gold therapy in rheumatoid arthritis: report of a multicentre controlled trial. Ann. Rheum. Dis., 20, 315– 354. Forestier, J. (1929). L'aurotherapie dan les rheumatismes chroniques. Bull. Soc. Med. Hop. Paris, 53, 323– 327. Fraser, T. N. (1945). Gold treatment in rheumatoid arthritis. Ann. Rheum. Dis., 4, 71– 75. Freedman, A. (1956). Chloroquine and rheumatoid arthritis: a short term controlled trial. Ann. Rheum. Dis., 15, 251– 256. Furst, D. E. (1990). Rational use of disease-modifying anti-rheumatic drugs. Drugs, 39, 19– 37. Gibson, T., Emery, P., Armstrong, R., Crisp, A. & Panayi, G. (1986). Combined chloroquine and d-penicillamine in rheumatoid arthritis—better or worse? Br. J. Rheumatol., 25, 114– 115. Grimaldi, M. G. (1981). Long-term low dose haloperidol treatment in rheumatoid patients: effects on serum sulphydryl levels, technetium index, ESR and clinical response. Br. J. clin. Pharmac., 12, 579– 581. Gutierrez-Rodriguez, O., Starusta-Bacal, P. & Gutierrez-Montes, O. (1989). Treatment of refractory rheumatoid arthritis—the thalidomide experience. J. Rheumatol., 16, 158– 163. Hamilton, E. B. D. & Scott, J. T. (1962). Hydroxychloroquine sulfate (plaquenil) in rheumatoid arthritis. Arthritis Rheum., 5, 502– 512. Haunzeur, J. P. & Appelboom, T. (1989). Double-blind placebo-controlled study of OM-8980 in rheumatoid arthritis. Rheumatol. Int., 9, 71– 76. Hartfall, S. J., Garland, H. E. & Goldie, W. (1937a). Gold treatment of arthritis; a review of 900 cases. Lancet, ii, 784– 788. Hartfall, S. J., Garland, H. E. & Goldie, W. (1937b). Gold treatment of arthritis; a review of 900 cases. Lancet, ii, 838– 842. Healy, L. A. & Wilske, K. R. (1989). Reforming the pyramid. A plan for treating rheumatoid arthritis in the 1990s. Rheumatic Disease Clinics of North America, 15, 615– 619. Hess, E. V. & Luggen, M. E. (1989). Remodelling the pyramid—A concept whose time has not yet come. J. Rheumatol., 16, 1175– 1176. Kirwan, J. R., de Saintong, Chaput D. M., Joyce, C. R. B. & Currey, H. L. F. (1984). Clinical judgement in rheumatoid arthritis III. British rheumatologist's judgements of 'change in response to therapy'. Ann. Rheum. Dis., 43, 686– 694. Kuzell, W. K. & Gardner, G. H. (1950). Salicylazosulfapyridine (salazopyrin or azopyrin) in rheumatoid arthritis and experimental polyarthritis. California Medicine, 73, 476– 480. Martin, M., Dixon, J., Hickling, P., Bird, H. A., Golding, J. & Wright, V. (1982a). A combination of d-penicillamine and hydroxychloroquine in the management of rheumatoid arthritis. Ann. Rheum. Dis., 41, 208. Martin, M., Sitton, N., Dixon, J., Hickling, P., Golding, J. & Wright, V. (1982b). Penicillamine failures—what can be done? Ann. Rheum. Dis., 41, 631– 632. Martin, M. F. R., Surrall, K. E., McKenna, F., Dixon, J. S., Bird, H. A. & Wright, V. (1984). Captopril: a new treatment for rheumatoid arthritis? Lancet, i, 1325– 1327. McConkey, B., Amos, R. S., Butler, R. A., Crockson, R. A., Crockson, A. P. & Walsh, L. (1978). Salazopyrine in rheumatoid arthritis. Agents & Actions, 8, 438– 441. McConkey, B., Davies, P., Crockson, R. A., Crockson, A. P., Butler, M. & Constable, T. J. (1976). Dapsone in rheumatoid arthritis. Rheumatol. Rehab., 15, 230– 234. McConkey, B. & Situnayake, D. (1988). Effects of rifampicin with and without isoniazid in rheumatoid arthritis. J. Rheumatol., 15, 46– 50. Mortiboy, D. & Palmer, R. G. (1989). Ciprofloxacin and rheumatoid arthritis—lack of effect. Br. J. Rheumatol., 28, 272. Multicentre Study Group (1978). Levamisole in rheumatoid arthritis. A randomised double-blind study comparing 2 dosage regimes of levamisole with placebo. Lancet, ii, 1007– 1012. Multicentre Trial Group (1973). Controlled trial of D(-) penicillamine in severe rheumatoid arthritis. Lancet, i, 275– 280. Neumann, V. C., Taggart, A. J., Le Gallez, P., Astbury, C., Hill, J. & Bird, H. A. (1986). A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J. Rheumatol., 13, 285– 287. Nuki, G. (1983). Non-steroidal analgesic and anti-inflammatory agents. Br. med. J., 287, 39– 43. Pasero, G., Pellegrini, P., Ambanelli, U., Gompi, M. L., Colamussi, V., Ferraccioli, G., Barbieri, P., Mazzoni, M. R., Menegale, G. & Trippi, D. (1982). Controlled multicenter trial of tiopronin and d-penicillamine for rheumatoid arthritis. Arthritis & Rheumatism, 25, 923– 929. Page, F. (1951). Treatment of lupus erythematosus with mepacrine. Lancet, ii, 755– 758. Pattrick, M., Heptinstall, S. & Doherty, M. (1989). Feverfew in rheumatoid arthritis: a double blind placebo-controlled study. Ann. Rheum. Dis., 48, 547– 549. Polson, R. J., Jawad, A. S. M., Bomford, A., Berry, H. & Williams, R. (1986). Treatment of rheumatoid arthritis with desferrioxamine. Quart. J. Med., 61, 153– 1158. Pullar, T., Hunter, J. A. & Capell, H. A. (1983). Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br. med. J., 287, 1102– 1104. Pullar, T., Hunter, J. A. & Capell, H. A. (1984). Does second line therapy affect the radiological progression of rheumatoid arthritis? Ann. Rheum. Dis., 43, 18– 23. Pullar, T. & Capell, H. A. (1985). A rheumatological dilemma: is it possible to alter the course of rheumatoid arthritis? Can we answer the question? Ann. Rheum. Dis., 44, 134– 140. Pullar, T., Hunter, J. A. & Capell, H. A. (1985a). Which is the active component of sulphasalazine in rheumatoid arthritis? Br. med. J., 290, 1535– 1538. Pullar, T., Hunter, J. A. & Capell, H. A. (1985b). Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br. J. Rheumatol., 24, 269– 276. Pullar, T., Hunter, J. A., & Capell, H. A. (1985c). Second line therapy in rheumatoid arthritis—A four year prospective study. Clin. Rheumatol., 4, 133– 142. Pullar, T. & Capell, H. A. (1986). Selection of suitable patients for second line therapy in rheumatoid arthritis. Br. J. Rheumatol., 25, 276– 281. Pullar, T., Peaker, S., Martin, M. F. R., Bird, H. A. & Feely, M. P. (1988). The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Br. J. Rheumatol., 27, 381– 384. Pullar, T. (1990). Decision making in the choice of second line agents. Europe/UK. In Second line agents in the treatment of arthritis, eds J. S. Dixon & D. E. Furst New York: Marcel Dekker. (in press). Ralston, S. H., Hacking, L., Willocks, L., Bruce, F. & Pitkeathly, D. A. (1989). Clinical, biochemical and radiographic effects of aminohydroxypropylidene biphosphate treatment in rheumatoid arthritis. Ann. Rheum. Dis., 48, 396– 399. Richards, I. M., Fraser, S. M., Hunter, J. A. & Capell, H. A. (1987). Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis. Ann. Rheum. Dis., 46, 667– 669. Scott, D. L., Spector, T. D., Pullar, T. & McConkey, B. (1989). What should we hope to achieve when treating rheumatoid arthritis? Ann. Rheum. Dis., 48, 256– 261. Scott, D. L., Dacre, J. E., Greenwood, A., Treasure, L. & Huskisson, E. C. (1990). Can we develop single response criteria for slow acting antirheumatic drugs. Ann. Rheum. Dis., 49, 196– 198. Sievers, K. & Hurri, L. (1963). Combined therapy of rheumatoid arthritis with gold and chloroquine. Evaluation of therapeutic effect. Acta med. Scand., 9, 48– 52. Sinclair, R. J. G. & Duthie, J. J. R. (1949). Salazopyrin in the treatment of rheumatoid arthritis. Ann. Rheum. Dis., 8, 226– 231. Situnayake, R. D., Grindulis, K. A. & McConkey, B. (1987). Long term treatment of rheumatoid arthritis with sulphasalazine, gold or penicillamine: a comparison using life-table methods. Ann. Rheum. Dis., 46, 177– 183. Spector, T. D., Thompson, P. W., Evans, S. J. W. & Scott, D. L. (1988). Are slow-acting antirheumatic drugs being given earlier in rheumatoid arthritis? Br. J. Rheumatol., 27, 498– 499. Svartz, N. (1942). Salazopyrin, a new sulfanilamide preparatation. Acta med. Scand., 110, 577– 598. Symmons, D. P. M., Pullar, T., Scott, D. L., Coulton, B. L., Hill, J. & Studnicka, A. (1989). Second-line drug therapy—what constitutes a satisfactory response? Br. J. Rheumatol., 28 (Abstract Suppl. 2), 117– 118. Taggart, A. J., Hill, J., Astbury, C., Dixon, J. S., Bird, H. A. & Wright, V. (1987). Sulphasalazine alone or in combination with d-penicillamine in rheumatoid arthritis. Br. J. Rheumatol., 26, 32– 36. Van der Heijde, D. M., Van Riel, P. L., Nuver-Swart, H. H., Gribnau, F. W. & van de Putte, L. B. (1989). Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet, i, 1036– 1038. Van der Heijde, D. M. F. M., Van Riel, P. L., Nuver-Swart, H. H. & van de Putte, L. B. A. (1990). Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet, i, 539. Walshe, J. M. (1956). Penicillamine, a new oral therapy for Wilson's disease. Am. J. Med., 21, 487– 495. Weinblatt, M. E., Coblyn, J. S., Fraser, P. A., Anderson, R. J., Spragg, J., Trentham, D. E. & Austin, K. E. (1987). Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis & Rheumatism, 30, 11– 17. Weiss, M. W. (1989). Corticosteroids in rheumatoid arthritis. Seminars in Arthritis & Rheumatism, 19, 9– 21. Wright, V. (1984). Oral gold for rheumatoid arthritis. Br. med. J., 289, 858– 859. Citing Literature Volume30, Issue4October 1990Pages 501-510 ReferencesRelatedInformation
Referência(s)